Telesis Bio 

$1.25
24
+$1.2+2,172.73% Today

Statistics

Day High
0.01
Day Low
0.01
52W High
1.55
52W Low
0
Volume
3
Avg. Volume
486
Mkt Cap
2.22M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

8MayExpected
Q1 2023
Q2 2023
Q3 2023
Q1 2024
Q2 2024
Q3 2024
Q1 2025
-7.62
-5.08
-2.54
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-178.21%Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
55.02MRevenue
-98.05MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TBIO. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap18.99B
Illumina provides sequencing and array-based solutions for genetic analysis, directly competing in the genomics space with Telesis Bio's technologies.
Pacific Biosciences of California
PACB
Mkt Cap702.87M
Pacific Biosciences offers long-read sequencing technologies, competing with Telesis Bio in the genomic sequencing market.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a direct competitor to Telesis Bio's gene editing and engineering solutions.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the genome editing field, making it a competitor to Telesis Bio in the development of gene editing technologies.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is a leading gene editing company, competing with Telesis Bio in the CRISPR/Cas9 gene editing space.
Twist Bioscience
TWST
Mkt Cap1.99B
Twist Bioscience specializes in synthetic DNA, directly competing with Telesis Bio in the synthetic biology and gene synthesis market.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics focuses on genomic medicine, including gene editing, competing in the same space as Telesis Bio.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics is involved in base editing, a form of gene editing, positioning it as a competitor to Telesis Bio in the gene editing technology sector.
Adaptive Biotechnologies
ADPT
Mkt Cap2.64B
Adaptive Biotechnologies is focused on the immune-driven medicine space, indirectly competing with Telesis Bio by offering complementary and competing genomic and diagnostic solutions.

About

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Show more...
CEO
Mr. Eric Esser
Employees
39
Country
US
ISIN
US1920032000

Listings

0 Comments

Share your thoughts

FAQ

What is Telesis Bio stock price today?
The current price of TBIO is $1.25 USD — it has increased by +2,172.73% in the past 24 hours. Watch Telesis Bio stock price performance more closely on the chart.
What is Telesis Bio stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Telesis Bio stocks are traded under the ticker TBIO.
Is Telesis Bio stock price growing?
TBIO stock has risen by +2,172.73% compared to the previous week, the month change is a +2,400% rise, over the last year Telesis Bio has showed a +240.32% increase.
What is Telesis Bio market cap?
Today Telesis Bio has the market capitalization of 2.22M
What is Telesis Bio revenue for the last year?
Telesis Bio revenue for the last year amounts to 55.02M USD.
What is Telesis Bio net income for the last year?
TBIO net income for the last year is -98.05M USD.
How many employees does Telesis Bio have?
As of February 02, 2026, the company has 39 employees.
In which sector is Telesis Bio located?
Telesis Bio operates in the Health Care sector.
When did Telesis Bio complete a stock split?
The last stock split for Telesis Bio was on May 09, 2024 with a ratio of 1:18.
Where is Telesis Bio headquartered?
Telesis Bio is headquartered in San Diego, US.